A Phase 3 interventional study of Investigational sIPV and Control IPV in Poliomyelitis, sponsored by Sinovac Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 60 Days to 90 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-25.
Sponsored by Sinovac Biotech Co., Ltd · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd — 2 open to participants now, 3 under way, none of them phase 3. Poliomyelitis · Sinovac Biotech Co., Ltd.
Among the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd, this one is the 5th largest by enrollment of the 13 interventional ones that give a count, is the only one that started in 2017, is one of 6 in phase 3, and was the 2nd registered.
275 studies on the registry are indexed under Poliomyelitis; 19 are open to participants now.
Browse Poliomyelitis studies →2 of the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:
Sinovac Biotech Co., Ltd · Sites in Philippines
Ages 56 days–84 days · Healthy volunteers
Sinovac Biotech Co., Ltd · Sites in China
Ages 3 mo–50 yrs · Healthy volunteers
By country, each count listing its studies:
Of the 11 Poliomyelitis studies recruiting now, none (0%) set no upper age limit and 11 (100%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.
This study: 60 Days to 90 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 1 started in 2017.
This study's enrollment of 1,200 is above the median of 478 across 250 interventional studies indexed under Poliomyelitis.
Median enrollment 708 across the 13 interventional studies, 342 across the 2 observational. Of the 12 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sinovac Biotech Co., Ltd is the lead sponsor of 93 studies on the registry; 18 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Poliomyelitis by Sinovac Biotech Co., Ltd, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this phase III study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) in 2-month-old infants.
The study is a randomized, double-blind, controlled randomized, double-blind, controlled clinical trial clinical trial. The purpose of this study is to evaluate the immunogenicity and safety of Sabin Inactivated Poliovirus Vaccine (Vero cell) manufactured by Sinovac Vaccine Technology Co., Ltd in 2-month-old infants. The control vaccine is a commercialized Inactivated Poliovirus Vaccine manufactured by Sanofi Pasteur company. 1200 healthy infants between 60-90 days will be randomly assigned into experimental group or control group in the ratio 1:1.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The investigational vaccine was manufactured by Sinovac Vaccine Technology Co., Ltd. Intervention: investigational sIPV
Biological: Investigational sIPV
The control vaccine was manufactured by Sanofi Pasteur Company. Intervention: control IPV
Biological: Control IPV
Three intramuscular injections of the investigational vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the investigational vaccine (0.5 ml) at 18 months; Intervention: investigational sIPV
Three intramuscular injections of the control vaccine (0.5 ml) on Day 0, Day 30 and Day 60 respectively; Single intramuscular injection of the control vaccine (0.5 ml) at 18 months; Intervention:control IPV
The seroconversion rates (SCRs) of each group after primary immunization.
Subjects whose pre-immune antibody level \< 1:8 and post-immune antibody level ≥ 1:8, or those whose pre-immune antibody level ≥ 1:8 and the increase of post-immune antibody level ≥ 4 folds are considered seroconverted. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
Time frame: 90 days
The incidences of solicited adverse events (AEs) of each group.
Solicited AEs occurred within 7 days after each injection will be collected.
Time frame: 7 days
The incidences of unsolicited adverse events (AEs) of each group.
Unsolicited AEs occurred within 30 days after each injection will be collected.
Time frame: 30 days
The incidence of serious adverse events (SAEs) during the period of safety monitoring of each group.
SAEs during the period of safety monitoring will be collected.
Time frame: 90-420 days.
The post-immune antibody positive rate of each group after primary immunization.
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. Primary vaccination schedule: 3 doses with one month interval between doses (i.e., month 0, 1, 2).
Time frame: 90 days
The post-immune geometric mean titer (GMT) of each group after primary immunization.
GMT of each group after primary immunization which lasts 60 days.
Time frame: 90 days.
The geometric mean fold increase (GMI) of each group after primary immunization.
The GMI is the increase of post-immune GMT from pre-immune GMT.
Time frame: 90 days
The percentage of subjects with antibody ≥ 1:64 of each group after primary immunization.
Percentage of subjects with antibody ≥ 1:64 of each group after three-dose
Time frame: 90 days
The antibody positive rate of each group before booster dose.
Subjects whose post-immune antibody level ≥ 1:8 are considered antibody positive. A booster dose at the age of 18months.
Time frame: 420 days
The geometric mean titer (GMT) of each group before booster dose.
GMT of each group before booster dose which occurred at the age of 18months.
Time frame: 420 days.
The geometric mean fold increase (GMI) of each group before booster dose.
The GMI is the increase of post-immune GMT from pre-i mmune GMT.
Time frame: 420 days
The percentage of subjects with antibody ≥ 1:64 of each group before booster dose.
Percentage of subjects with antibody ≥ 1:64 of each group before booster dose which occurred at the age of 18months.
Time frame: 420 days
The post-immune antibody positive rate of each group after booster dose.
Subjects whose post-immune antibody level ≥ 1:8 are co nsidered antibody positive
Time frame: 570 days
The post-immune geometric mean titer (GMT) of each group after booster dose.
GMT of each group after booster dose. The booster dose at the age of 18months
Time frame: 570 days
The geometric mean fold increase (GMI) of each group after booster dose.
The GMI is the increase of post-immune GMT from pre-immune GMT.
Time frame: 570 days
The percentage of subjecs with antibody ≥ 1:64 of each group after booster dose.
Percentage of subjecs with antibody ≥ 1:64 of each group after booster dose which occurred at the age of 18months.
Time frame: 570 days
Ran from Aug 2017 to primary completion in Oct 2017, 2 months.
Of 36 industry-sponsored phase 3 interventional studies under Poliomyelitis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 21. This study's 2 months is below that.
Counting every sponsor, half of 45 studies reached it within 12 months; a quarter within 7 and three quarters within 21.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.